A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06625190 |
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT04742010 |
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS) |
COMPLETED | PHASE2 |
| NCT03735537 |
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid |
COMPLETED | PHASE4 |
| NCT02516423 |
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone |
TERMINATED | PHASE3 |
